Malignant phase hypertension is defined clinically as a high blood pressure associated with bilateral retinal flame-shaped haemorrhages and/or exudates or cotton wool spots, with or without papilloedema. 1 What makes one person's blood pressure very high but without the malignant phase (unfortunately referred to as 'benign' hypertension), whilst another person's very high blood pressure manifests itself as malignant hypertension? It is not the level of blood pressure alone which determines whether or not a patient has malignant hypertension, as the blood pressure in severe 'benign' hypertension may be quite as high as in malignant hypertension. The hallmark of malignant hypertension is the presence of fibrinoid necrosis of arterioles in many tissue beds, a process not seen in 'benign' hypertension.
The importance of diagnosing malignant hypertension lies in the fact that, if untreated, it carries a very poor prognosis with a 5-year survival rate of 1%. 2 Effective treatment has led to substantial improvements in survival with the prognosis at 5 years being reported to be between 60% 3 and 75% 4, 5 in developed countries. In developing countries such as Nigeria, the prognosis appears to be considerably worse 6 with 1-year survival rates of only 40%. When compared to controls with non-malignant hypertension matched for blood pressure, there still remains a substantial excess of morbidity and mortality associated with malignant hypertension. 3 This re-emphasises the importance of detection, recognition and appropriate management of the problem, as malignant hypertension usually affects relatively young people with a mean age of 50 years in one series. 7 So what has happened to malignant hypertension? With improvements in the screening and modern treatment of hypertension, malignant hypertension has been described as a 'vanishing disease', 5, 8 and some clinicians in western developed populations Correspondence: Dr GYH Lip Received and accepted 15 November 1999 even claim they never see the condition. Malignant hypertension still appears to be common in some developing countries, 9 but one epidemiological anomaly is apparent -malignant hypertension is still commonly seen in Birmingham, England, which most would like to regard as a developed country. 7 Closer examination of clinical epidemiology of the Birmingham malignant hypertension series of approximately 450 patients reveals a high first generation migrant population, with a high prevalence of Afro-Caribbean, Indian and Pakistani patients, living in an area of socio-economic deprivation. The high prevalence in Afro-Caribbeans may be an important factor, in view of the high incidence of hypertension and its complications (renal failure, stroke) in this ethnic group 4 and since these patients tend to present with malignant hypertension with higher blood pressures and greater renal impairment. In some ways, the Birmingham series has many similarities with series of malignant hypertension reported from countries such as South Africa. However in the Birmingham series, only 30% were non-Caucasian, suggesting that the high prevalence of malignant hypertension in Birmingham cannot be explained simply by the ethnic demography.
In this issue of the Journal of Human Hypertension, Kadiri et al 10 report a series of 74 patients with essential malignant hypertension who were compared with matched patients with benign essential hypertension. In those with a history of hypertension diagnosed prior to presentation with malignant hypertension, the duration of known hypertension was shorter than in the non-malignant hypertension controls, suggesting that malignant hypertension may have developed fairly acutely. Indeed, observations that a significant proportion of malignant hypertension patients who do not have left ventricular hypertrophy on the ECG or echocardiogram, or cardiomegaly on the chest X-ray, at presentation would be in keeping with this hypothesis. 4 In addition, socio-economic factors leading to delayed diagnosis and under-treatment of hypertension seem to play an important role in the development of malignant hypertension. Kadiri et al 10 observe that the patients with malignant hypertension were more likely to be from lower socio-economic groups, with higher stress exposure and have inadequate antihypertensive therapy prior to presentation. They identified 'high stress' by asking their patients about selfperceived stress, which opens the possibility of recall bias. An association between stress and malignant hypertension has been previously reported. For example, Sesoko et al 11 investigated the histories of 39 patients with malignant hypertension and noted that insufficient sleep, overwork and mental burden were prominent factors in a substantial number of these patients. These findings raise the possibility that the sympathetic nervous system may have an important role in the development of the disease.
It appears that malignant hypertension can recur in the same patient if the blood pressure is poorly controlled and allowed to rise again, 11, 12 which suggests that there may be some unknown factor(s) which determines whether or not patients will develop the disease. Furthermore, there are some differences in the underlying aetiologies of malignant and benign hypertension, in that secondary causes of hypertension are commonly found (approximately 40%) in malignant hypertension, whereas they are uncommon in benign hypertension (5%). 7, 13 Interestingly, smoking and oral contraceptive pill usage did not confer an increased risk of malignant hypertension in the paper by Kadiri et al, 10 which is in keeping with reports from the Birmingham series, 7, 14 but is in contrast to the Glasgow Blood Pressure clinic 15 and the earlier Birmingham series by Bloxham et al. 16 The many similarities between the South African series 10 and the latest Birmingham malignant hypertension series implies common aetiological factors, and perhaps low socio-economic status of the majority white population of the west of Birmingham as well as the high prevalence of Afro-Caribbean ethnic group may be factors. Perhaps the west of Birmingham, England, should declare itself as an area with 'developing country' status with regard to the clinical epidemiology of hypertension.
There is one other possible explanation for our findings of the failure of malignant hypertension to disappear in Britain. All undergraduates and physicians routinely use the ophthalmoscope in clinical practice in Britain. By contrast, in some countries opthalmoscopy is only carried out by ophthalmologists and this may lead to a significant underdiagnosis of malignant hypertension, particularly if a patient has no visual symptoms. It is possible therefore that there has been no real decline in malignant hypertension, but merely a failure to recognise this life-threatening condition.
Theoretically, this condition may be prevented by greater awareness and more aggressive treatment of hypertension. However, if this were true one would expect to see a decline in the incidence of malignant hypertension as primary care services improve. The latest British Hypertension guidelines 17 recommend that everyone's blood pressure should be checked every 5 years and if these guidelines are followed, then more premorbid or earlier hypertension may be diagnosed. It may then become apparent whether early treatment of mild to moderate hypertension will prevent the development of malignant hypertension.
Although our ability to treat hypertension has improved, malignant hypertension still remains an enigma. The precise clinical and pathophysiological factors contributing to the pathogenesis of malignant hypertension remains poorly understood. Perhaps under-detection and inadequate management of hypertension, in association with poor socio-economic status remains the common denominatorsfor still a small but significant proportion of hypertensives still develop malignant hypertension and most are not previously known to have raised blood pressure and are receiving no treatment. The incidence of malignant hypertension can only decline if the routine measurement of blood pressure in all citizens becomes an integral part of good medical care.
